Curtit Elsa, Benhamo Vanessa, Gruel Nadège, Popova Tatiana, Manie Elodie, Cottu Paul, Mariani Odette, Stoppa-Lyonnet Dominique, Pivot Xavier, Stern Marc-Henri, Vincent-Salomon Anne
Department of Medical Oncology, Institut Curie, 75248 Paris, France.
Department of Medical Oncology, University Hospital, 25000 Besançon, France.
Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
We describe the case of a woman carrying a germline pathogenic BRCA1 mutation diagnosed with a breast cancer overexpressing HER2. Clinical presentation of the tumor, HER2-positivity, genomic profile and loss of the mutated BRCA1 allele in tumor evidence that BRCA1 is not inactivated in this breast cancer. It represents the first biological demonstration for the existence of a sporadic HER2-positive breast cancer independent from BRCA loss of function in a woman carrier of a deleterious BRCA1 mutation. In a context where targeted therapies based on BRCA loss of function in the tumor are developed, such case could have direct implications.
我们描述了一例携带生殖系致病性BRCA1突变的女性病例,该女性被诊断患有HER2过表达的乳腺癌。肿瘤的临床表现、HER2阳性、基因组图谱以及肿瘤中突变的BRCA1等位基因的缺失表明,BRCA1在这种乳腺癌中并未失活。这是首次在携带有害BRCA1突变的女性中,从生物学角度证明存在与BRCA功能丧失无关的散发性HER2阳性乳腺癌。在基于肿瘤中BRCA功能丧失开发靶向治疗的背景下,此类病例可能具有直接影响。